The Exploding RNAi Market & Future Direction Translating the Genome into a Large Market by 2009

Table of Contents

1. US RNAi Market & Business Models

• 1.1 Overview of RNA Interference
  • 1.1.2 Double Stranded RNA (dsRNA)
  • 1.1.3 Short interfering RNA; Small interfering RNA (siRNA)
  • 1.1.4 Short Hairpin RNA (shRNA)
  • 1.1.5 DNA-directed RNAi (ddRNAi)
  • 1.1.6 MicroRNA (miRNA)
• 1.2 Current US RNAi Market & Key Customer Applications
  • 1.2.1 The Current US RNAi Market
  • 1.2.2 RNAi as a Tool for Conventional Drug Discovery
  • 1.2.3 RNAi as a Tool for Conventional Drug Development
  • 1.2.4 RNAi as a Tool in Basic Research
  • 1.2.5 RNAi as Therapeutics
• 1.3 Competitive Landscape
  • 1.3.1 Market Map of Major Players 19
  • 1.3.2 Major Players by Focus Segment and Product Strategy
  • 1.3.3 Research Finding & Analysis
    • 1.3.3.1 Market Leaders
    • 1.3.3.2 Future Promised Application, Trend
    • 1.3.3.3 Strong Technology: Big Picture
    • 1.3.3.4 Best Business Model & Product Development Strategy

2. Alliance and M&A Activities

• 2.1 Analysis of RNAi Alliance and M&A Activities, 2003 to Nov-2005
• 2.2 RNAi Alliances and M&As (2003 to Nov-2005)
• 2.3 Legal: Intellectual Property and Regulatory Approval
  • 2.3.1 Intellectual Property
  • 2.3.2 Regulatory Approval
• 2.4 Researcher Finding: Companies to Watch for Future R&D
  • 2.4.1 RNAi Technology Companies on the Move
  • 2.4.2 Big Pharma is Starting to Get Involved in RNAi

3. Market Assessment and Trends

• 3.1 Total US RNA Interference (RNAi) Market Size 2004-2009
• 3.2 US RNAi Market by Segments
  • 3.2.1 RNAi Market By Application Segments
    • 3.2.1.2 RNAi in Basic Research
    • 3.2.1.3 RNAi in Drug Discovery
    • 3.2.1.4 RNAi in Drug Development
    • 3.2.1.5 RNAi Therapeutics
  • 3.2.2 RNAi Application Segment Market Shares, 2005 & 2009
  • 3.2.3 RNAi Market By Major Disease Segments
    • 3.2.3.1 Cancer
    • 3.2.3.2 Infections 54
    • 3.2.3.3 Metabolic
    • 3.2.3.4 Eye disease
    • 3.2.3.5 CNS
    • 3.2.3.6 Respiratory
    • 3.2.3.7 Inflammation
    • 3.2.3.8 Bone Diseases
    • 3.2.3.9 Blood Disease
    • 3.2.3.10 Cardiovascular
  • 3.2.3.11Diagnostics, Skin Conditions and Others
  • 3.2.4 Major Disease Segment Market Shares (%), 2005 & 2009
  • 3.2.5 RNAi Market By Product Segments
    • 3.2.5.1 RNAi Reagents & Related Services
    • 3.2.5.2 RNAi Delivery Tools & Devices
    • 3.2.5.3 Assay Systems
    • 3.2.5.4 Cell Lines & Related
    • 3.2.5.5 Discovery Techs, Services & Drugs
    • 3.2.5.6 Genomewide RNAi HT/ HC Screening Tools
  • 3.2.6 RNAi Product Segment Market Shares (%), 2005 & 2009
• 3.3 Key Trends/ Future Directions
  • 3.3.1 Big Pharma Starting to Get Involved in RNAi
  • 3.3.2 Advances Made in Dealing With Off-target Effects
  • 3.3.3 Little Is Known about microRNA Functionality
  • 3.3.4 Direct Delivery of RNAi-based Drugs
  • 3.3.5 Systemic Delivery of RNAi Drugs
  • 3.3.4 RNAi Future Direction Timeline

4. Activities of RNAi-Based Companies

• 4.1 RNAi in Basic Research (5)
• 4.2 RNAi in Drug Discovery (5)
• 4.3 RNAi Drug Development & Therapeutics (11)

5. Findings and Suggestions

• 5.1 Review of Findings and Key Trends
  • 5.1.1 RNAi Technology
  • 5.1.2 Competitive Landscape
  • 5.1.3 Alliances
  • 5.1.4 Patents
  • 5.1.5 Market Assessment
• 5.2 Recommendations to Capture Opportunities
• 5.3 Current Status: Products Urgently Needed by RNAi Users in R&D
• 5.4 Future Market Prospects

6. Appendix

• 6.1 RNAi Glossary
• 6.2 Company Contacts

• Table 1. Diseases Targeted by Direct Delivery of RNAi Drugs
• Table 2. Diseases Targeted by Systemic Delivery of RNAi Drugs
• Table 3. Major Players in the RNAi Market
• Table 4. Major Players by Focus Segment and Product Strategy
• Table 5. Summary of RNAi Alliances and M&As, 2003 to Nov-2005
• Table 6. Alliances and M&As, 2005
• Table 7. Alliances and M&As, 2004
• Table 8. Alliances and M&As, 2003
• Table 9. RNAi Related Patent Applications, ' 03-' 05
• Table 10. Key Patents for RNAi Reagents and Drugs
• Table 11. Selected RNAi IP Disputes
• Table 12. RNAi Therapeutics In /(or Near) Clinical Trials
• Table 13. RNAi Technology Companies To Watch for R&D
• Table 14. RNAi Alliances Among Big Pharmas
• Table 15. US RNAi Market Size By Total Revenues ($M), 2004-2009 50
• Table 16. US RNAi Market By Application Segment Revenues ($M), 2004-2009
• Table 17. Application Segment Market Shares (%), 2005 & 2009
• Table 18. RNAi Market By Major Disease Segments, Revenues ($M), 2004-2009
• Table 19. Major Disease Segment Market Shares (%), 2005 & 2009
• Table 20. RNAi Market By Product Segments, Revenues ($M), 2004-2009
• Table 21. Product Segment Market Shares (%), 2005 & 2009
• Table 22. RNAi R&D Unmet Needs - Selected Opportunity Matrix

• Figure 1. Timeline for Key RNAi Technology Developments
• Figure 2. Central Theme of Modern Biology, DNA encodes for Proteins
• Figure 3. The RNAi Process with dsRNA, shRNA, siRNA and RISC
• Figure 4. RNAi R&D Market by Major Applications
• Figure 5. RNAi Related Patent Applications, ' 03-' 05
• Figure 6. New Drug Approval Timeline and Roadmap
• Figure 7. US RNAi Market Size By Total Revenues ($M), 2004-2009
• Figure 8. US RNAi Market By Application Segment Revenues ($M), 2004-2009
• Figure 9. RNAi Application Segment Market Shares (%), 2005 & 2009
• Figure 10. RNAi Market By Major Disease Segments, Revenues ($M), 2004-2009
• Figure 11. Major Disease Segment Market Shares (%), 2005 & 2009
• Figure 12. RNAi Market By Product Segments, Revenues ($M), 2004-2009
• Figure 13. Product Segment Market Shares (%), 2005 & 2009
• Figure 14. RNAi Future Direction Timeline 2005-2009